203 related articles for article (PubMed ID: 37305036)
21. Current and emerging therapies for PNETs in patients with or without MEN1.
Frost M; Lines KE; Thakker RV
Nat Rev Endocrinol; 2018 Apr; 14(4):216-227. PubMed ID: 29449689
[TBL] [Abstract][Full Text] [Related]
22. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
[TBL] [Abstract][Full Text] [Related]
23. First surgery for pancreatic neuroendocrine tumours in a patient with MEN1: enucleation versus disease-modifying surgery.
Harper S; Harrison B
Clin Endocrinol (Oxf); 2015 Nov; 83(5):618-21. PubMed ID: 25807996
[TBL] [Abstract][Full Text] [Related]
24. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial.
Bahig H; Yuan Y; Mohamed ASR; Brock KK; Ng SP; Wang J; Ding Y; Hutcheson K; McCulloch M; Balter PA; Lai SY; Al-Mamgani A; Sonke JJ; van der Heide UA; Nutting C; Li XA; Robbins J; Awan M; Karam I; Newbold K; Harrington K; Oelfke U; Bhide S; Philippens MEP; Terhaard CHJ; McPartlin AJ; Blanchard P; Garden AS; Rosenthal DI; Gunn GB; Phan J; Cazoulat G; Aristophanous M; McSpadden KK; Garcia JA; van den Berg CAT; Raaijmakers CPJ; Kerkmeijer L; Doornaert P; Blinde S; Frank SJ; Fuller CD
Clin Transl Radiat Oncol; 2018 Nov; 13():19-23. PubMed ID: 30386824
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK.
Teoh S; Ooms A; George B; Owens R; Chu KY; Drabble J; Robinson M; Parkes MJ; Swan L; Griffiths L; Nugent K; Good J; Maughan T; Mukherjee S
BMJ Open; 2023 Sep; 13(9):e068906. PubMed ID: 37709321
[TBL] [Abstract][Full Text] [Related]
26. B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors.
Braden B; Jenssen C; D'Onofrio M; Hocke M; Will U; Möller K; Ignee A; Dong Y; Cui XW; Sãftoiu A; Dietrich CF
Endosc Ultrasound; 2017; 6(1):49-54. PubMed ID: 28218201
[TBL] [Abstract][Full Text] [Related]
27. Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study.
Kappelle WF; Valk GD; Leenders M; Moons LM; Bogte A; Siersema PD; Vleggaar FP
Endoscopy; 2017 Jan; 49(1):27-34. PubMed ID: 27975336
[No Abstract] [Full Text] [Related]
28. Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study.
Tamagno G; Scherer V; Caimo A; Bergmann SR; Kann PH
Digestion; 2018; 98(2):112-118. PubMed ID: 29698969
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience.
Oleinikov K; Uri I; Jacob H; Epshtein J; Benson A; Ben-Haim S; Atlan K; Tal I; Meirovitz A; Maimon O; Lev-Cohain N; Mazeh H; Glaser B; Gross DJ; Grozinsky-Glasberg S
Endocrine; 2020 Apr; 68(1):222-229. PubMed ID: 32036501
[TBL] [Abstract][Full Text] [Related]
30. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?
Qiu W; Christakis I; Stewart AA; Vodopivec DM; Silva-Figueroa A; Chen H; Woodard TL; Halperin DM; Lee JE; Yao JC; Perrier ND
Clin Endocrinol (Oxf); 2017 Jun; 86(6):791-797. PubMed ID: 28273369
[TBL] [Abstract][Full Text] [Related]
31. Rupture of small cystic pancreatic neuroendocrine tumor with many microtumors.
Sagami R; Nishikiori H; Ikuyama S; Murakami K
World J Gastroenterol; 2017 Oct; 23(37):6911-6919. PubMed ID: 29085235
[TBL] [Abstract][Full Text] [Related]
32. Comparison of MR-guided radiotherapy accumulated doses for central lung tumors with non-adaptive and online adaptive proton therapy.
Rabe M; Palacios MA; van Sörnsen de Koste JR; Eze C; Hillbrand M; Belka C; Landry G; Senan S; Kurz C
Med Phys; 2023 May; 50(5):2625-2636. PubMed ID: 36810708
[TBL] [Abstract][Full Text] [Related]
33. Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group.
Nell S; Verkooijen HM; Pieterman CRC; de Herder WW; Hermus AR; Dekkers OM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
Ann Surg; 2018 Jun; 267(6):1155-1160. PubMed ID: 28257328
[TBL] [Abstract][Full Text] [Related]
34. Dosimetric feasibility of hippocampal avoidance whole brain radiotherapy with an MRI-guided linear accelerator.
Graham JA; Redler G; Delozier KB; Yu HM; Oliver DE; Rosenberg SA
J Appl Clin Med Phys; 2022 Jun; 23(6):e13587. PubMed ID: 35344266
[TBL] [Abstract][Full Text] [Related]
35. Initial clinical experience with magnetic resonance-guided radiotherapy in pediatric patients: Lessons learned from a single institution with proton therapy.
Hall MD; Mittauer KE; Herrera R; Von Werne K; Kotecha R; Kalman NS; McCulloch J; Alvarez D; McAllister NC; Doty DG; Rzepczynski AE; Deere W; Gutierrez AN; Chuong MD
Front Oncol; 2022; 12():1037674. PubMed ID: 36713501
[TBL] [Abstract][Full Text] [Related]
36. Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.
Civil YA; Oei AL; Duvivier KM; Bijker N; Meijnen P; Donkers L; Verheijen S; van Kesteren Z; Palacios MA; Schijf LJ; Barbé E; Konings IRHM; -van der Houven van Oordt CWM; Westhoff PG; Meijer HJM; Diepenhorst GMP; Thijssen V; Mouliere F; Slotman BJ; van der Velde S; van den Bongard HJGD
BMC Cancer; 2023 May; 23(1):419. PubMed ID: 37161377
[TBL] [Abstract][Full Text] [Related]
37. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
38. Spleen and splenic vessel preserving distal pancreatectomy for bifocal PNET in a young patient with MEN1.
Conrad C; Schwarz L; Perrier N; Fleming JB; Katz MH; Aloia TA; Vauthey JN; Lee JE
Surg Endosc; 2016 Oct; 30(10):4619. PubMed ID: 26721691
[TBL] [Abstract][Full Text] [Related]
39. Management of pancreatic neuroendocrine tumors in patients with MEN 1.
Sadowski SM; Triponez F
Gland Surg; 2015 Feb; 4(1):63-8. PubMed ID: 25713781
[TBL] [Abstract][Full Text] [Related]
40. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
